Incentives given to substitutive dispensing for drugs proven of their bio-equivalency.

Published: 2001-06-25 06:59:00

Updated: 2001-06-25 06:59:00

The Health Insurance Review Agency (HIRA) reported to the National Assembly on June 20 that a certain rate of incentives be given to pharmacists when dispensing expensive drugs for a low priced substitutive drugs proven of bio-equivalency in order to restrict expensive drug prescriptions, and the...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK